Also on the agenda are Hta in rare diseases, IVD and companion
diagnostics, while a hot topic will be the role of Hta for better patient access to personalised medicine.
Traditionally there has been the initial Hta to assess market authorization,
but there should also be a comparative or full Hta later, not only for reimbursement purposes
but also to support appropriate use.